Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma treatments, offering allergy immunotherapy and related products and services [2] - The company is headquartered in Hørsholm, Denmark, and employs approximately 2,800 people worldwide [2] Financial Calendar - The financial calendar for ALK includes key dates such as: - 23 January 2026: Silent period begins - 20 February 2026: Annual report for 2025 is scheduled for release - 16 March 2026 at 4:00 p.m.: Annual General Meeting [4] - Additional reporting dates include: - 5 May 2026: Three-month interim report (Q1) for 2026 - 20 August 2026: Six-month interim report (Q2) for 2026 - 18 November 2026: Nine-month interim report (Q3) for 2026 [5] AGM Participation - Written requests for specific business transactions to be included in the AGM agenda must be received by the company by 30 January 2026 [1]

Financial Calendar - Columbus Financial Calendar for 2026 includes key dates such as the Annual Report on 12 March 2026, Annual General Meeting on 23 April 2026, and Interim Reports for Q1, Q2, and Q3 on 7 May, 20 August, and 5 November 2026 respectively [1] - After the publication of financial statements, the company will conduct an investor presentation via a conference call and webcast [1] Annual General Meeting - Columbus A/S's annual general meeting is scheduled for Thursday, 23 April 2026, at Lautrupvang 6, 2750 Ballerup, starting at 10:00 [2] Contact Information - For further inquiries, the CEO & President, Søren Krogh Knudsen, can be contacted at +45 70 20 50 00 [3]